CURED

CURED Inc. is a Japanese biopharmaceutical company specializing in the development of next-generation immunological therapeutics for oncology, infectious diseases, and inflammatory conditions. Spun out from Yokohama City University, the company leverages a proprietary network to identify and advance pharmaceutical "seeds" from academic institutions into clinical candidates. Its pipeline features humanized CAR-T and CAR-NK cell therapies targeting antigens such as EVA1 and NKp44L for solid tumors and brain cancers, as well as a small molecule NLRP3 inhibitor for chronic kidney diseases like Alport syndrome. Additionally, CURED utilizes innovative production platforms, including transgenic silkworms, to manufacture high-potency antibodies for the curative treatment of chronic HIV infections.